<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02943239</url>
  </required_header>
  <id_info>
    <org_study_id>R2477-1033-HV-1621</org_study_id>
    <secondary_id>2016-002979-95</secondary_id>
    <nct_id>NCT02943239</nct_id>
  </id_info>
  <brief_title>Study of Safety, Tolerability, and Pharmacokinetics of REGN2477 Alone and in Combination With REGN1033 in Healthy Postmenopausal Women</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacodynamics Effects of REGN2477 Alone and in Combination With REGN1033 in Healthy Postmenopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assess the safety and tolerability of REGN2477 alone and combined with REGN1033 in health
      postmenopausal women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Assess the safety and tolerability of REGN2477 alone and combined with REGN1033 in health
      postmenopausal women.

      Effect of REGN2477 alone, REGN1033 alone and REGN2477+REGN1033 in combination on muscle and
      body composition.

      Measure amount of REGN2477 and REGN1033 in blood.

      Assess presence or absence of antibodies for REGN2477 or REGN1033.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 7, 2016</start_date>
  <completion_date type="Anticipated">October 5, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 14, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>From baseline to week 16</time_frame>
    <description>Incidence and severity of treatment-emergent adverse events (TEAEs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change in thigh muscle volume as measured by MRI</measure>
    <time_frame>From baseline to week 8</time_frame>
    <description>Percent change in thigh muscle volume as measured by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in thigh muscle volume as measured by MRI</measure>
    <time_frame>From baseline to week 8</time_frame>
    <description>Change in thigh muscle volume as measured by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in total and regional body composition as measured by DXA</measure>
    <time_frame>From baseline to week 8</time_frame>
    <description>Percent change in total and regional body composition as measured by DXA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total body composition as measured by DXA</measure>
    <time_frame>From baseline to week 8</time_frame>
    <description>Change in total body composition as measured by DXA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in regional body composition as measured by DXA</measure>
    <time_frame>From baseline to week 8</time_frame>
    <description>Change in regional body composition as measured by DXA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of REGN2477 assessed via measurement of concentrations of REGN2477 in serum over time</measure>
    <time_frame>From baseline to week 16</time_frame>
    <description>Pharmacokinetic profile of REGN2477</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of REGN1033 assessed via measurement of concentrations of REGN1033 in serum overtime</measure>
    <time_frame>From baseline to week 16</time_frame>
    <description>Pharmacokinetic profile of REGN1033</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total Activin A levels in blood</measure>
    <time_frame>From baseline to week 16</time_frame>
    <description>Change in total Activin A levels in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total GDF8 levels in blood</measure>
    <time_frame>From baseline to week 16</time_frame>
    <description>Change in total GDF8 levels in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence or absence of antibodies against REGN2477 and REGN1033</measure>
    <time_frame>From baseline to week 16</time_frame>
    <description>Presence or absence of antibodies against REGN2477 and REGN1033</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Panel A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>REGN1033 + REGN2477 (Regimen 1) or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Panel B - REGN1033 + REGN2477 (Regimen 2) or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Panel C - Patients will receive either REGN1033 + REGN2477 (Regimen 3) or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Panel D - Patients will receive either REGN1033 + REGN2477 (Regimen 4), REGN1033, REGN2477 (high dose) or Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REGN1033</intervention_name>
    <description>REGN1033</description>
    <arm_group_label>Panel A</arm_group_label>
    <arm_group_label>Panel B</arm_group_label>
    <arm_group_label>Panel C</arm_group_label>
    <arm_group_label>Panel D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REGN2477</intervention_name>
    <description>REGN2477</description>
    <arm_group_label>Panel A</arm_group_label>
    <arm_group_label>Panel B</arm_group_label>
    <arm_group_label>Panel C</arm_group_label>
    <arm_group_label>Panel D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Panel A</arm_group_label>
    <arm_group_label>Panel B</arm_group_label>
    <arm_group_label>Panel C</arm_group_label>
    <arm_group_label>Panel D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal women age 45 to 70 years

          -  BMI between 18 to 32 kg/m2, inclusive

          -  Willing and able to maintain current diet, supplements and physical activity level
             throughout the study

          -  Provides signed informed consent

        Exclusion Criteria:

          -  Significant illness or history of significant illness

          -  Contraindication to MRI

          -  History of human immunodeficiency virus (HIV); hepatitis B or hepatitis C virus (HCV)

          -  History of immobilization, major surgical procedure, fracture, or major trauma within
             9 months prior to screening

          -  History of significant gynecological disorders or malignancies; history of breast
             malignancies (uterine fibroids or dysfunctional uterine bleeding is acceptable)

          -  Inconsistent vigorous physical activity (on fewer than 5 days per week), such as
             intermittent weight lifting

          -  History of hypersensitivity reactions to tetracycline antibiotics (includes
             doxycycline), vaccines, or biologics

          -  Use of agents that alter muscle mass that have not been at a stable dose for 3 months
             prior to screening (includes protein supplements), or use of any weight altering or
             anabolic steroid drugs (includes drugs for obesity, diuretics, testosterone)

          -  Patients treated with a biologic therapy or biologic immunotherapy in the previous 12
             weeks prior to screening and during the study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 19, 2016</study_first_submitted>
  <study_first_submitted_qc>October 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2016</study_first_posted>
  <last_update_submitted>November 2, 2017</last_update_submitted>
  <last_update_submitted_qc>November 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

